BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2027300)

  • 21. Preferential suppression of low molecular weight natural tumor suppressor of human fetal liver origin on the growth of leukemic cells in vitro.
    Pei XT; Wu CT
    Exp Hematol; 1990 Sep; 18(8):927-31. PubMed ID: 2387343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
    Wisniewski D; Strife A; Atzpodien J; Clarkson BD
    Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of in vitro inhibition of etoposide (VP16) on leukemic and normal myeloid, erythroid clonogenic cells.
    Lagneaux L; Marie JP; Delforge A; Socquet M; Thevenin D; Zittoun R; Stryckmans P
    Exp Hematol; 1989 Aug; 17(7):843-6. PubMed ID: 2753092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of methylcellulose on colony growth of human myeloid leukemic progenitors (AML-CFU).
    Allieri MA; Douay L; Deloux J; Smadja N; Najman A; Gorin NC
    Exp Hematol; 1990 Sep; 18(8):911-5. PubMed ID: 2387341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of bryostatin 1 on the in vitro radioprotective capacity of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) toward committed human myeloid progenitor cells (CFU-GM).
    Grant S; Pettit GR; McCrady C
    Exp Hematol; 1992 Jan; 20(1):34-42. PubMed ID: 1374343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.
    Gordon MY; Marley SB; Lewis JL; Davidson RJ; Nguyen DX; Grand FH; Amos TA; Goldman JM
    J Clin Invest; 1998 Aug; 102(4):710-5. PubMed ID: 9710439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
    Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
    Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heat sensitivity, thermotolerance and protein synthesis of granulocyte and macrophage progenitors from mice and from long-term bone marrow cultures.
    Mivechi NF; Li GC
    Int J Hyperthermia; 1990; 6(3):529-41. PubMed ID: 2376666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discordant maturation as the primary biological defect in chronic myelogenous leukemia.
    Strife A; Lambek C; Wisniewski D; Wachter M; Gulati SC; Clarkson BD
    Cancer Res; 1988 Feb; 48(4):1035-41. PubMed ID: 3422181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells.
    Grant S; Traylor R; Bhalla K; McCrady C; Pettit GR
    Leukemia; 1992 May; 6(5):432-9. PubMed ID: 1593908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
    Minderman H; Linssen P; van der Lely N; Wessels J; Boezeman J; de Witte T; Haanen C
    Leukemia; 1994 Mar; 8(3):382-7. PubMed ID: 8127143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage.
    Wierenga PK; Konings AW
    Exp Hematol; 1996 Feb; 24(2):246-52. PubMed ID: 8641348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral blood progenitor cell mobilisation alters myeloid, but not erythroid, progenitor cell self-renewal kinetics.
    Marley SB; Lewis JL; Zheng B; Davidson RJ; Davis JG; McDonald C; Alenzi FQ; Goldman JM; Gordon MY
    Bone Marrow Transplant; 2001 Feb; 27(3):241-8. PubMed ID: 11277171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of H-7 and staurosporine on proliferation and self-renewal of acute myeloid leukemia progenitors.
    Laredo J; Demur C; Muller C; Saivin S; Cassar G; Bousquet C; Dastugue N; Jaffrézou JP; Colombies P; Laurent G
    Leukemia; 1993 Jun; 7(6):813-20. PubMed ID: 8501977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells.
    Van Der Lely N; De Witte T; Muus P; Raymakers R; Preijers F; Haanen C
    Exp Hematol; 1991 May; 19(4):267-72. PubMed ID: 2055291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Experimental bases of the in vitro treatment of leukemic bone marrow by a derivative of cyclophosphamide: ASTA Z 7557].
    Douay L; Gorin NC; Mary JY; Duhamel G
    C R Acad Sci III; 1985; 301(6):303-8. PubMed ID: 3928107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor.
    Broxmeyer HE; Cooper S; Williams DE; Hangoc G; Gutterman JU; Vadhan-Raj S
    Exp Hematol; 1988 Aug; 16(7):594-602. PubMed ID: 3260558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GM-CSF enhances sensitivity of leukemic clonogenic cells to long-term low dose cytosine arabinoside with sparing of the normal clonogenic cells.
    De Witte T; Muus P; Haanen C; Van der Lely N; Koekman E; Van der Locht A; Blankenborg G; Wessels J
    Behring Inst Mitt; 1988 Aug; (83):301-7. PubMed ID: 3071344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.